Janney Montgomery Scott
CRSP icon

Janney Montgomery Scott’s CRISPR Therapeutics CRSP Stock Holding History

Janney Montgomery Scott’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
23,168
+860
+4% +$45.3K ﹤0.01% 1771
2026
Q1 		$1.06M Buy
22,308
+16
+0.1% +$844 ﹤0.01% 1617
2025
Q4 		$1.17M Buy
22,292
+2,925
+15% +$175K ﹤0.01% 1642
2025
Q3 		$1.25M Buy
19,367
+5,782
+43% +$332K ﹤0.01% 1560
2025
Q2 		$661K Buy
13,585
+2,882
+27% +$112K ﹤0.01% 1838
2025
Q1 		$364K Buy
10,703
+3,827
+56% +$162K ﹤0.01% 2193
2024
Q4 		$271K Sell
6,876
-966
-12% -$45.6K ﹤0.01% 2367
2024
Q3 		$368K Sell
7,842
-2,771
-26% -$141K ﹤0.01% 2165
2024
Q2 		$573K Buy
10,613
+1,631
+18% +$94.3K ﹤0.01% 1787
2024
Q1 		$612K Sell
8,982
-281
-3% -$20.1K ﹤0.01% 1828
2023
Q4 		$580K Sell
9,263
-3,824
-29% -$211K ﹤0.01% 1785
2023
Q3 		$594K Buy
13,087
+5,964
+84% +$308K ﹤0.01% 1651
2023
Q2 		$400K Buy
7,123
+1,927
+37% +$109K ﹤0.01% 2034
2023
Q1 		$235K Buy
+5,196
New +$252K ﹤0.01% 2196
2022
Q4 		– Sell
-10,677
Closed -$698K – 2581
2022
Q3 		$698K Buy
10,677
+48
+0.5% +$3.48K ﹤0.01% 1488
2022
Q2 		$673K Buy
10,629
+511
+5% +$30K ﹤0.01% 1443
2022
Q1 		$635K Sell
10,118
-230
-2% -$14.4K ﹤0.01% 1496
2021
Q4 		$784K Sell
10,348
-6,914
-40% -$604K ﹤0.01% 1470
2021
Q3 		$1.93M Buy
17,262
+2,519
+17% +$316K 0.01% 969
2021
Q2 		$2.39M Buy
14,743
+1,118
+8% +$136K 0.01% 869
2021
Q1 		$1.66M Buy
13,625
+6,732
+98% +$1.02M 0.01% 971
2020
Q4 		$1.05M Sell
6,893
-155
-2% -$18.3K 0.01% 1152
2020
Q3 		$589K Buy
7,048
+1,203
+21% +$107K ﹤0.01% 1354
2020
Q2 		$430K Buy
5,845
+541
+10% +$31.6K ﹤0.01% 1439
2020
Q1 		$225K Sell
5,304
-3,552
-40% -$183K ﹤0.01% 1625
2019
Q4 		$539K Buy
8,856
+3,866
+77% +$211K ﹤0.01% 1389
2019
Q3 		$205K Buy
+4,990
New +$238K ﹤0.01% 1886

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Janney Montgomery Scott's CRSP Position: Q2 2026 in Review

Janney Montgomery Scott increased its CRISPR Therapeutics (CRSP) stake by 3.9% in Q2 2026, buying an estimated $45.3K and bringing the position to 23,168 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

Janney Montgomery Scott first reported a position in CRSP in Q3 2019 and has held it in 27 quarters since. The position peaked at $2.39M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Janney Montgomery Scott held 23,168 shares of CRISPR Therapeutics worth $1.26M as of Q2 2026.
  • Janney Montgomery Scott bought 860 CRISPR Therapeutics shares in Q2 2026, an estimated $45.3K.
  • CRISPR Therapeutics made up ﹤0.01% of Janney Montgomery Scott's portfolio in Q2 2026, its #1771 holding.
  • Janney Montgomery Scott first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • Janney Montgomery Scott's CRISPR Therapeutics position peaked at $2.39M in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Janney Montgomery Scott's 13F filing for Q2 2026, filed 5 Aug 2026.